2005 Fiscal Year Final Research Report Summary
Research for clinical application of gene therapy for head and neck cancer
| Project/Area Number |
14370543
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Kobe University |
|---|
Principal Investigator |
NIBU Ken-ichi Kobe University, Graduate School of Medicine Department of Otolaryngology-Head and Neck Surgery, Professor, 大学院・医学系研究科, 教授 (20251283)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
OTSUKI Naoki Kobe University, Hospital, Associate Professor, 医学部附属病院, 講師 (40343264)
|
|---|
| Project Period (FY) |
2002 – 2005
|
| Keywords | head and neck cancer / gene therapy / adenoviral vector / COX-2 |
|---|
| Research Abstract |
Objective : To teat the oncolytic activity of COX2-promoter based conditional replication-selective adenovirus vector for squamous cell carcinoma cells of head and neck.
Subjects : A conditional replication-selective adenovirus vector in which the expression of Ela, required for viral replication, is controlled by the COX-2 promoter, Ad-COX2-Ela, was generated. Its oncolytic activity according to the levels of COX-2 and CAR (Coxsackie and adenovirus receptor) expression was tested in a series of human head and neck squamous cell carcinoma cell lines.
Results
The respective COX-2 mRNA expression ratios of KB, H891, T891, T892, and L871 were 1.5, 60, 1, 14.6, and 1.3. The corresponding CAR mRNA expression ratios were 1, 1, 5, 4, and 3. In vitro assays showed significant growth suppression of cancer cell lines with strong expressions of COX-2. In addition, Ad-COX2-Ela showed significant growth suppression of COX-2 expressing tumors in vivo model.
Cenclusions
In this study, we demonstrated the possibility of oncolytic therapy using the COX-2 promoter based conditional replication-selective adenovirus for head dnd neck squamous cell carcinoma expressing COX-2.
|
